HEALTHCARE VENTURES II HAS $95 MIL. FOR FUNDING UP TO EIGHT
HEALTHCARE VENTURES II HAS $95 MIL. FOR FUNDING UP TO EIGHT health care product companies. Operated by HealthCare Investment Corporation of Edison, New Jersey, the fund recently announced the closing of $81.4 mil. in limited partnership interests. Since that closing at the beginning of the year, the fund has raised another $14 mil. HealthCare Ventures II is a followup to a predecessor fund which raised and distributed $60.3 mil., with investments in 10 start-up firms. The general partners of Ventures II are Walter Steinberg (previously VP of J&J Development Corp.), James Cavanaugh (a former president of SK&F Labs and a top White House aide in the Ford Administration), James Burns (previously a Group VP at Becton Dickinson in charge of biotech and emerging products), and Harold Werner (also from J&J Development). Cavanaugh is serving as president of the corporation that runs the two venture funds. With about $160 mil. combined, Ventures I and II claim to represent the largest venture capital pool devoted exclusively to health care investments. Ventures II is designed to organize start-up and early stage biotech health care companies. The target for initial funding is$2.5 mil. to $4 mil. per investment. The fund management expects to initiate the corporate development in about three-quarters of the firms that it will back. Ventures II "will provide the technical depth, industry experience and management capability necessary to develop high value companies that can generate superior rates of return," a prospectus for the fund declares. Ventures II intends to focus on nine market areas: diabetes management; transplant medicine; substance abuse treatment; non-destructive sterilization of blood and blood substitutes; anti-sense drugs; cardiovascular drugs; neuroscience drugs; and anti-viral drugs. Among its investment criteria are target markets of more than $200 mil. worldwide, annual revenue potential of $30 mil. to $100 mil., protectable products, and "a potential for liquidity in three to five years at a valuation in excess of $100 mil."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth